Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.86 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.86 |
| ▸ | PRKCA | P17252 | 13/20 | 0.89 |
| ▸ | MEN1 | O00255 | 6/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.89 |
| ▸ | LMNA | P02545 | 5/20 | 0.89 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.89 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.89 |
| ▸ | GMNN | O75496 | 4/20 | 0.89 |
| ▸ | POLB | P06746 | 4/20 | 0.89 |
| ▸ | MAPT | P10636 | 4/20 | 0.89 |
| ▸ | APEX1 | P27695 | 4/20 | 0.89 |
| ▸ | RECQL | P46063 | 4/20 | 0.89 |
| ▸ | BLM | P54132 | 4/20 | 0.89 |
| ▸ | PMP22 | Q01453 | 4/20 | 0.89 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.89 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.89 |
| ▸ | GLA | P06280 | 2/20 | 0.89 |
| ▸ | TP53 | P04637 | 3/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Laurolinium SCHEMBL29388527 | 0.99 | PRKCA (0.88) | PRKCAMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL19490053 | 0.99 | PRKCA (0.88) | PRKCAMEN1KMT2ALMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9789749 | 0.97 | MEN1 (0.89) | PRKCAMEN1KMT2ALMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL32681974 | 0.97 | MEN1 (0.89) | PRKCAMEN1KMT2ALMNASMN1; SMN2 | |
| Iodide SCHEMBL2331911 | 0.94 | PRKCA (0.83) | PRKCAMEN1KMT2ALMNASMN1; SMN2 | |
| Iodide SCHEMBL6298119 | 0.94 | PRKCA (1.00) | PRKCAMEN1KMT2ALMNASMN1; SMN2 | |
| Dequalinium SCHEMBL2335922 | 0.94 | PRKCA (1.00) | PRKCAMEN1KMT2ALMNASMN1; SMN2 | |
| Iodide SCHEMBL29496899 | 0.94 | PRKCA (1.00) | PRKCAMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL6299633 | 0.93 | PRKCA (1.00) | PRKCAMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL6298118 | 0.93 | PRKCA (1.00) | PRKCAMEN1KMT2ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12247246-B2 | Identification of inhibitors of TcpC and TIR NADase activity | WASHINGTON UNIVERSITY (US) | 2025-03-11 | — | — | US | disclosed |
| US-20230272449-A1 | IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY | WASHINGTON UNIVERSITY | 2023-08-31 | — | — | US | disclosed |
| US-20200283820-A1 | IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY | WASHINGTON UNIVERSITY | 2020-09-10 | — | — | US | disclosed |
| US-20190298841-A1 | Nucleic Acid Complexes | PROCARTA BIOSYSTEMS LTD (GB) | 2019-10-03 | — | — | US | disclosed |
| US-10350299-B2 | Nucleic acid complexes | PROCARTA BIOSYSTEMS LTD. (GB) | 2019-07-16 | — | — | US | disclosed |
| WO-2019067625-A1 | IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADASE ACTIVITY | WASHINGTON UNIVERSITY (US) | 2019-04-04 | — | — | WO | disclosed |
| US-20170340745-A1 | NUCLEIC ACID COMPLEXES | PROCARTA BIOSYSTEMS LTD. (GB) | 2017-11-30 | — | — | US | disclosed |
| US-9669101-B2 | Nucleic acid complexes | PROCARTA BIOSYSTEMS LTD (GB) | 2017-06-06 | — | — | US | disclosed |
| US-9550991-B2 | Transcription factor decoys | PROCARTA BIOSYSTEMS LTD. (GB) | 2017-01-24 | — | — | US | disclosed |
| EP-2552455-B1 | TRANSCRIPTION FACTOR DECOYS | PROCARTA BIOSYSTEMS LTD (GB) | 2016-12-28 | — | — | EP | disclosed |
| US-20130252881-A1 | Transcription Factor Decoys | PROCARTA BIOSYSTEMS LTD. (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130059775-A1 | Nucleic Acid Complexes | PROCARTA BIOSYSTEMS LTD (GB) | 2013-03-07 | — | — | US | disclosed |
| EP-2552455-A2 | TRANSCRIPTION FACTOR DECOYS | Procarta Biosystems Ltd (GB) | 2013-02-06 | — | — | EP | disclosed |
| EP-2533815-A1 | NUCLEIC ACID COMPLEXES | Procarta Biosystems Ltd (GB) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011121357-A2 | TRANSCRIPTION FACTOR DECOYS | PROCARTA BIOSYSTEMS LIMITED (GB) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011098829-A1 | NUCLEIC ACID COMPLEXES | PROCARTA BIOSYSTEMS LTD (GB) | 2011-08-18 | — | — | WO | disclosed |
| US-6974871-B2 | Dequalinium analogs | THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2005-12-13 | — | — | US | disclosed |
| US-6790962-B2 | SUNSCREEN AGENTS | THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK | 2004-09-14 | — | — | US | disclosed |
| US-20030118529-A1 | Novel dequalinium analogs | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK | 2003-06-26 | — | — | US | disclosed |
| US-20020114769-A1 | Novel dequalinium analogs | RESEARCH FOUNDATION OF THE CITY, THE | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230272449-A1 | IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY | NADK, NAPRT, TIPARP | CHRM1 4424/4885ACHE 3265/4885PRKCA 2174/4885 |
| US-10350299-B2 | Nucleic acid complexes | ZFR, SUB1, RELA | CHRM1 4877/4885ACHE 4834/4885PRKCA 4524/4885 |
| US-12247246-B2 | Identification of inhibitors of TcpC and TIR NADase activity | NADK, NAPRT, TIPARP | CHRM1 4424/4885ACHE 3265/4885PRKCA 2174/4885 |
| US-20170340745-A1 | NUCLEIC ACID COMPLEXES | ZFR, SUB1, RELA | CHRM1 4877/4885ACHE 4834/4885PRKCA 4524/4885 |
| US-20030118529-A1 | Novel dequalinium analogs | XPA, XPO1, XPO6 | CHRM1 48/4885ACHE 3410/4885PRKCA 4455/4885 |
| US-20200283820-A1 | IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY | NADK, NAPRT, TIPARP | CHRM1 4424/4885ACHE 3265/4885PRKCA 2174/4885 |
| US-20190298841-A1 | Nucleic Acid Complexes | ZFR, SUB1, RELA | CHRM1 4877/4885ACHE 4834/4885PRKCA 4524/4885 |
| US-20020114769-A1 | Novel dequalinium analogs | QTRT1, QTRT2, CACNA1A | CHRM1 29/4885ACHE 3053/4885PRKCA 4470/4885 |
| US-20130059775-A1 | Nucleic Acid Complexes | ZFR, SUB1, RELA | CHRM1 4877/4885ACHE 4834/4885PRKCA 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.